Document:

EX-10.2

 Exhibit 10.2 

SEPARATION AND RELEASE AGREEMENT 

In consideration of the promises and mutual undertakings contained herein, and other good and valuable consideration, the
receipt and sufficiency of which the parties hereby acknowledge, the parties to this Separation and Release Agreement (the “Agreement”), David M. Fronk (“Employee”) and CryoLife, Inc. (“CryoLife” or the
“Company”), hereby agree as follows: 
 1. CryoLife terminated Employee’s employment, effective
September 24, 2015 (the “Termination Date”). 
 2. In consideration of Employee’s release of CryoLife of any and all
claims as further specified below, entry into the restrictive covenants set forth below, and the other covenants and undertakings herein, CryoLife agrees to take each of the following actions: 

a. Pay Employee the total gross amount of $283,000, after the Effective Date, pursuant to the schedule below. The
“Effective Date” of this Agreement will be the date following the expiration of the seven (7)-day revocation period referenced below. 
  

	 	(i)	 A separate payment of $23,583.33 on October 30, 2015; 

 

	 	(ii)	 A separate payment of $23,583.33 on November 30, 2015; 

 

	 	(iii)	 A separate payment of $23,583.33, and December 31, 2015; and 

 

	 	(iv)	 The remaining balance paid as a separate lump sum on January 29, 2016. 

b. Pay Employee a lump sum in the amount of $19,783, which is an amount equivalent to 12 months of COBRA coverage, such amount
to be paid on the first pay day following the Effective Date. 
 c. Provide up to twelve (12) months of outplacement
services through an outplacement provider selected by Employee and approved by the Company, in an amount not to exceed $15,000. 

Employee acknowledges that the consideration set forth in this paragraph shall be the sole monetary obligation that CryoLife
has to him following his execution of this Agreement, and that he shall have no further claim to monies of any kind, whether representing vacation pay, bonuses, stock, or otherwise, unless such claim is not permitted to be waived by law. 

Notwithstanding anything to the contrary set forth above, because of his separation, Employee shall be entitled to the
benefits that accrue upon retirement pursuant to the Company’s Stock Plans (including, for avoidance of doubt, with respect to the Stock Plans, his options granted pursuant to Option Agreements, which shall remain exercisable, but only to the
extent vested as of the Termination Date, until the earlier of the end of the applicable option term or thirty-six (36) months from the Termination Date, and otherwise in accordance with the applicable Option Agreement). 

All payments to Employee shall be subject to normal deductions and withholdings where applicable. Further, the parties agree
that CryoLife makes no representations or warranties to Employee with respect to the tax consequences (including but not limited to income tax 

  
 1 

 
consequences) contemplated by this Agreement or the payment of any benefits hereunder, and that CryoLife has no responsibility to take or refrain from taking any actions in order to achieve a
certain tax result for Employee. 
 3. In consideration of the covenants from CryoLife to Employee set forth above, the
receipt and sufficiency of which are hereby acknowledged, Employee agrees to release and forever discharge CryoLife and all of its present and former officers, directors, partners, employees, agents, insurers, affiliates, attorneys, parents,
subsidiaries, and representatives (hereafter, the “Released Parties”) from any and all claims and causes of action (including but not limited to costs and attorneys’ fees) of whatever kind or nature, joint or several, under any
federal, state or local statute, ordinance or under the common law, including, but not limited to, the Age Discrimination in Employment Act, the Older Workers’ Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Civil Rights
Act of 1991, the Americans with Disabilities Act, any claim for retaliation or wrongful discharge of employment as a result of any present or future claim of whistleblower status under the Dodd-Frank Act or any analogous state statute (provided that
nothing herein shall prevent Employee from reporting any concerns that he might have that are protected activities under the Dodd-Frank Act, nor is this Agreement designed to impede such activity by Employee), and any other employment discrimination
law, state or federal, as well as any other claims based on constitutional, statutory, common law or regulatory grounds, that Employee has now or may have in the future against the Released Parties, whether known or unknown, which are based on acts
or facts arising or occurring prior to the Effective Date of this Agreement. 
 a. Nothing in this Agreement shall be
construed as prohibiting Employee from making a claim with the Equal Employment Opportunity Commission or any similar or equivalent state agency or the National Labor Relations Board, or from filing a whistleblower or other report with the United
States or a state Department of Labor or other governmental administrative agency, or from assisting any third-party, by providing truthful testimony, in pursuit of such future claim, action or lawsuit of any kind. Notwithstanding the foregoing,
should Employee pursue any such administrative claim or otherwise assist any third-party in the pursuit of such administrative claim, action or lawsuit of any kind, Employee, to the maximum extend allowed by law, agrees and acknowledges that he will
not seek, and hereby waives and forfeits, any right to recover monetary damages associated with any such claim, action or proceeding. 

b. Employee represents and warrants that neither Employee nor anyone acting on Employee’s behalf has filed or initiated
any charge, claim or lawsuit against the Released Parties in any administrative or judicial proceeding. 
 4. In further
consideration of the covenants from CryoLife to Employee set forth above, the receipt and sufficiency of which are hereby acknowledged, Employee agrees to the following: 

a. Definitions. For the specific purpose of the covenants contained in this Section and for all other purposes under
this Agreement, certain terms are defined as follows: 
 (1) “Company Business” shall mean and
include the allograft cardiac or vascular tissue processing business, the biological glue, powdered hemostat or protein hydrogel product business, and the transmyocardial revascularization business. 

(2) “Competing Business” shall mean any person or entity that is engaged in, or conducts, a business
substantially similar to the Company Business and only that portion of the business that is in competition with the Company Business. 

(3) “Confidential Information” shall mean, collectively, all “Proprietary Information” and
“Trade Secrets” of the Company. 

  
 2 

 (4) “Proprietary Information” shall mean all data,
formulae, processes, procedures, methods, documentation, information, records, drawings, designs, specifications, test results, evaluations, know-how, material directly related to sales processes, information risk management, tests or assays,
business, assets, products or prospects related to the Company and the Company Business, which is or was communicated to, supplied to, observed by or created by Employee, either directly or indirectly, at any time during the employment relationship,
whether or not received from the Company or from any actual or potential customer or client of the Company, or from any person with a business relationship, whether contractual or otherwise, with the Company. The term “Proprietary
Information” shall not include any information that Employee can prove: (a) was known by Employee prior to the time of employment with the Company as long as such information was not acquired, either directly or indirectly, from the
Company; (b) is or becomes publicly known through no direct or indirect act, fault or omission of Employee; (c) is or becomes part of the public domain through no direct or indirect act, fault or omission of Employee; or (d) was
received by Employee from a third party having the legal right to transmit the same without restriction as to use and disclosure and such receipt was not in connection with any business relationship or prospective business relationship with the
Company or its Affiliates; provided, however, that a combination of features shall not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or otherwise within such exceptions, as previously
described, unless the combination itself is in the public domain or otherwise entirely within any one such exception. 

(5) “Territory” shall mean the geographic locations where the Employee performed work for the
Company, and the geographic locations where Employee’s work benefited the Company. 
 (6) “Trade
Secrets” shall mean information not generally known about the Company’s business which is the subject of efforts that are reasonable under the circumstances to maintain its secrecy or confidentiality and from which the Company derives
economic value from the fact that the information is not generally known to other persons who can obtain economic value from its disclosure or use, and shall include any and all Proprietary Information which may be protected as a trade secret under
any applicable law, even if not specifically designated as such. Trade Secrets may include, but are not limited to, technical or non-technical data, compilations, programs and methods, techniques, drawings, processes, financial data, lists of actual
customers and potential customers, customer route books, cards or lists containing the names, addresses, habits and business locations of past, present and prospective customers, sales reports, price lists, product formulae, methods and procedures
relating to services. 
 b. Acknowledgments. Employee acknowledges that: (i) the Company has expended
substantial time, money, effort and other resources to develop its goodwill, clients, business sources and relationships; (ii) the Company has a legitimate business interest in protecting the same; (iii) in connection with Employee’s
employment by the Company, the Company has introduced Employee to its customers, business sources and relationships and has expended considerable time, effort and capital to train Employee in the Company Business; (iv) by virtue of
Employee’s employment with the Company, Employee had contact with certain of the Company’s customers and business sources and relationships; (v) in Employee’s 

  
 3 

 
capacity, Employee may be privy to certain Confidential Information, Proprietary Information and Trade Secrets not generally known or available to the Company’s competitors or the general
public; (vi) the nature and periods of the restrictions imposed by the covenants contained in this Section are fair, reasonable, and necessary to protect and preserve for the Company and that such restrictions will not prevent Employee from
earning a livelihood; (vii) the Company would sustain great and irreparable loss and damage if Employee were in any manner to breach any of such covenants; (viii) the Company conducts its business actively in and throughout all
geographical areas included within the Territory and other persons are engaged in like and similar business in the Territory; and (ix) the Territory is reasonable because Employee’s responsibilities were performed throughout and benefited
the Territory. 
 c. Agreement Not to Compete. Employee covenants and agrees with the Company that Employee will not
at any time during the twenty-four (24) months after the Effective Date of this Agreement, either directly or indirectly perform work or services that are the same or substantially similar to those the employee performed for CryoLife, either as
an employee, owner, director, volunteer, or consultant, for any Competing Business in the Territory. 
 d. Agreement Not
to Divert Employees. Employee covenants and agrees with the Company that Employee will not, within the Territory, at any time during the twenty-four (24) months after the Effective Date of this Agreement, either directly or indirectly,
solicit, entice, persuade or induce, or attempt to solicit, entice, persuade or induce any person who is employed by the Company to terminate his or her employment or contractual arrangement with the Company. 

e. Protection of Confidential Information. Employee covenants and agrees that all Confidential Information (including
all Proprietary Information and Trade Secrets) and all physical embodiments thereof received or developed by Employee or disclosed to Employee while employed by the Company is confidential and is and will remain the sole and exclusive property of
the Company. Employee further covenants and agrees, for so long as such information remains confidential, to hold all Confidential Information in trust and in the strictest confidence, and will not use, reproduce, distribute, disclose or otherwise
disseminate the Confidential Information or any physical embodiments thereof and in no event shall Employee take any action causing or fail to take the action necessary in order to prevent any Confidential Information disclosed to or developed by
Employee to lose its character or cease to qualify as Confidential Information. Notwithstanding anything contained herein to the contrary, this covenant shall not limit in any manner the protection of the Company’s Trade Secrets otherwise
afforded by law. 
 f. Cooperation. Employee agrees to cooperate with CryoLife, during the twelve (12) months
following the Effective Date, by responding to reasonable requests by the Company for information and assistance and providing such information and/or assistance up to four (4) hours per week for no additional consideration other than the
benefits described in Section 2 above. Employee acknowledges that such cooperation may include timely completion of an officers and directors questionnaire provided by CryoLife. 

5. Employee agrees to return all Company property in Employee’s possession, custody or control immediately.
Notwithstanding anything to the contrary in this Agreement, no consideration will be payable under this Agreement until Employee has satisfied this obligation. 

6. Employee represents and warrants that as of the date of execution of this Agreement, Employee has not assigned or
transferred or purported to assign or transfer any of the claims released herein. Employee hereby agrees to indemnify and hold harmless the 

  
 4 

 
Released Parties against, without any limitation, any and all claims and causes of action (including, but not limited to, costs and attorneys’ fees), arising out of any such transfer or
assignment. 
 7. This Agreement and the covenants, representations, warranties and releases contained herein shall inure to
the benefit of and be binding upon Employee and CryoLife and each of their successors, heirs, assigns, agents, affiliates, parents, subsidiaries and representatives. 

8. This Agreement contains the entire agreement and understanding concerning the subject matter between the parties. Each
party acknowledges that no one has made any representation whatsoever not contained herein concerning the subject matter hereof, to induce the execution of this Agreement. This Agreement expressly supersedes, without limitation, any previously
executed Secrecy and Noncompetition Agreement and Change of Control Agreements between the Company and Employee. The applicable Option Agreements shall remain in effect as set forth herein. 

9. Employee acknowledges that the consideration for signing this Agreement is a benefit to which Employee would not have been
entitled without signing this Agreement. 
 10. Employee has the right to, and has been advised to, consult with an attorney
before signing this Agreement. Employee further acknowledges Employee’s understanding that Employee has twenty-one (21) days to consider the Agreement before signing it, that Employee may revoke this Agreement within seven
(7) calendar days after signing it, by delivering written evidence of such revocation to CryoLife within that seven (7)-day period, and that this Agreement will not be effective or enforceable until expiration of that seven (7)-day revocation
period. Revocation may be made by delivering written notice of revocation to the attention of Marian Schoenberg, Director, Human Resources at CryoLife, Inc., 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144. 

11. Employee agrees to refrain from making any disparaging remarks about CryoLife or Employee’s employment at CryoLife,
other than as may reasonably be necessary for fair competition or as referenced in Section 3. 
 12. Miscellaneous.

 a. Severability. In the event a court of competent jurisdiction finds any provision (or subpart thereof) (including
but not limited to the covenants referenced in Section 3) to be illegal or unenforceable, the parties agree that the court shall modify the provision(s) (or subpart(s) thereof) to make the provision(s) (or subpart(s) thereof) and this Agreement
valid and enforceable to the fullest extent permitted by law. Any illegal or unenforceable provision (or subpart thereof) shall otherwise be severable and shall not affect the validity of the remainder of such provision and any other provision of
this Agreement. 
 b. Modification, Governing Law; Waiver. This Agreement can only be modified by a writing signed by
the parties, and shall be interpreted in accordance with and governed by the laws of the State of Georgia (including Georgia’s new Restrictive Covenants Act) without regard to the choice of law provisions thereof. Any dispute arising out of or
relating to this Agreement, or the construction, enforceability or breach thereof, shall be brought only in a state or federal court sitting in Cobb County, Georgia. Employee hereby expressly consents to personal jurisdiction in said courts and
waives any objections to jurisdiction and venue of said courts for the resolution of disputes as described herein. Failure to assert or act upon any breach of this Agreement shall not constitute a waiver of the right to assert a future breach of the
Agreement or any portion thereof. 

  
 5 

 
c. Section 409A. This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (Section 409A) or an exemption thereunder and shall be
construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an
applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the
maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be
made upon a “separation from service” under Section 409A. Notwithstanding the foregoing, the Employer makes no representations that the payments and benefits provided under this Agreement comply with Section 409A and in no event
shall the Employer be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Employee on account of non-compliance with Section 409A. 

RECEIPT: 
 I acknowledge receipt of a copy of
this Separation and Release Agreement. Unless and until I execute this Agreement in the other space provided below, I have not agreed to it. 
  

							
		 	  
	 		 	                        
		 	 Signature for Purposes of Receipt Only
	 		 	            Date

  
 6 

 MY SIGNATURE BELOW SIGNIFIES MY UNDERSTANDING OF AND VOLUNTARY ASSENT TO THE TERMS OF THIS AGREEMENT. I
UNDERSTAND AND ACKNOWLEDGE THAT BY SIGNING THIS AGREEMENT, I MAY BE GIVING UP VALUABLE RIGHTS. 
  

					
		  		  	 /s/ David M. Fronk

		  		  	 David M. Fronk

			
	 Sworn to and subscribed before me this

     day of             , 2015.
	  	Date:	  	 October 7, 2015

			
	  
 Notary
Public
	  		  	

  

			
	 CryoLife, Inc.

		
	 By:
	 	 /s/ Marian Schoenberg

		 	 Marian Schoenberg

Director, Human Resources

		
	 Date:
	 	 October 8, 2015

  
 7EX-10.3

 Exhibit 10.3 

FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT 

AGREEMENT 

THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (“Amendment”) is entered into as of
September 28, 2015, by and among CryoLife, Inc. (“CryoLife”), CryoLife International, Inc. (“International”) and Aurazyme Pharmaceuticals, Inc. (“Auruzyme”, and together with CryoLife and
International, the “Borrowers”), CryoLife as Borrower Representative, the other Credit Parties party hereto, General Electric Capital Corporation, a Delaware corporation (the “Agent”), as administrative agent for
the lenders from time to time party to the Credit Agreement described below (collectively, the “Lenders” and individually each a “Lender”) and for itself as a Lender and L/C Issuer, and such Lenders. 

RECITALS 

A. Borrower Representative, the other Credit Parties signatory thereto, the Lenders signatory thereto from time to time and
Agent are parties to that certain Second Amended and Restated Credit Agreement, dated as of September 26, 2014 (as may be amended, supplemented, revised, restated, replaced or otherwise modified from time to time, the “Credit
Agreement”). Capitalized terms used in this Amendment without definition shall have the meanings ascribed to such terms in the Credit Agreement, as applicable. 

B. The Borrowers have requested that Lenders amend the Credit Agreement in certain respects and Lenders have agreed to so
amend the Credit Agreement, subject to the terms and conditions hereof. 
 NOW, THEREFORE, in consideration of the premises
and the mutual covenants hereinafter contained, and intending to be legally bound, the parties hereto agree as follows: 
 A.
AMENDMENTS 
 1. Amendment to Section 5.4. Section 5.4 of the Credit Agreement is hereby amended by
replacing subsection (b) of such Section in its entirety with the following: 
 (b)
extensions of credit by (i) any Credit Party to any other Credit Party, (ii) a Borrower or any Domestic Subsidiary of a Borrower to Foreign Subsidiaries of a Borrower not to exceed $3,000,000 in the aggregate at any time outstanding for
all such extensions of credit (including intercompany accounts receivable owed by Foreign Subsidiaries except to the extent such intercompany accounts receivable constitutes trade payables entered into in the ordinary course of business) provided,
if the extensions of credit described in foregoing clauses (i) and (ii) are evidenced by notes, such notes shall be pledged to the Agent, for the benefit of the Secured Parties, and have such terms as the Agent may reasonably require and
(iii) a Foreign Subsidiary of a Borrower to another Foreign Subsidiary of a Borrower; 

 B. CONDITIONS TO EFFECTIVENESS  

Notwithstanding any other provision of this Amendment and without affecting in any manner the rights of the Lenders hereunder,
it is understood and agreed that this Amendment shall not become effective, and the Borrowers shall have no rights under this Amendment, until Agent shall have received duly executed signature pages to this Amendment from the Lenders, Borrowers, L/C
Issuer, Agent and each Credit Party. 
 C. REPRESENTATIONS 

Each Credit Party hereby represents and warrants to Lenders, L/C Issuer and Agent that: 

1. The execution, delivery and performance by such Credit Party of this Amendment (a) are within such Credit Party’s
power; (b) have been duly authorized by all necessary corporate, limited liability company or limited partnership action; (c) are not in contravention of any provision of such Credit Party’s certificate of incorporation or bylaws or
other organizational documents; (d) do not violate any law or regulation, or any order or decree of any Governmental Authority; (e) do not conflict with or result in the breach or termination of, constitute a default under or accelerate
any performance required by, any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Credit Party or any of its Subsidiaries is a party or by which such Credit Party or any such Subsidiary or any of their
respective property is bound; (f) do not result in the creation or imposition of any Lien upon any of the property of such Credit Party or any of its Subsidiaries other than those in favor of Agent, on behalf of itself and the Lenders, pursuant
to the Loan Documents; and (g) do not require the consent or approval of any Governmental Authority or any other Person. 

2. This Amendment has been duly executed and delivered for the benefit of or on behalf of each Credit Party and constitutes a
legal, valid and binding obligation of each Credit Party, enforceable against such Credit Party in accordance with its terms except as the enforceability hereof may be limited by bankruptcy, insolvency, reorganization, moratorium and other laws
affecting creditors’ rights and remedies in general. 
 3. Except as disclosed in writing to the Agent on the date
hereof, both before and after giving effect to this Amendment, the representations and warranties contained in the Credit Agreement and the other Loan Documents are true and correct in all material respects and no Default or Event of Default has
occurred and is continuing as of the date hereof. 
 D. OTHER AGREEMENTS 

1. Continuing Effectiveness of Loan Documents. As amended hereby, all terms of the Credit Agreement and the other Loan
Documents shall be and remain in full force and effect and shall constitute the legal, valid, binding and enforceable obligations of the Credit Parties party thereto. To the extent any terms and conditions in any of the other Loan Documents shall
contradict or be in conflict with any terms or conditions of the Credit Agreement, after giving effect to this Amendment, such terms and conditions are hereby deemed modified and amended accordingly to reflect the terms and conditions of the Credit
Agreement 

  
 2 

 
as modified and amended hereby. Upon the effectiveness of this Amendment such terms and conditions are hereby deemed modified and amended accordingly to reflect the terms and conditions of the
Credit Agreement as modified and amended hereby. 
 2. Reaffirmation of Loan Documents. Each Credit Party consents to
the execution and delivery of this Amendment by all parties hereto and the consummation of the transactions described herein, and ratifies and confirms the terms of the Credit Agreement, that certain Guaranty and Security Agreement, dated as of
March 27, 2008, reaffirmed by that certain Omnibus Reaffirmation Agreement, dated as of October 28, 2011 and further reaffirmed by that certain Omnibus Reaffirmation Agreement, dated as of September 26, 2014 (as amended, supplemented
or modified, the “Guaranty and Security Agreement”) and each other Loan Document to which such Credit Party is a party with respect to the indebtedness now or hereafter outstanding under the Credit Agreement as amended hereby and
all promissory notes issued thereunder. Each Credit Party acknowledges that, notwithstanding anything to the contrary contained herein or in any other document evidencing any indebtedness of any Borrower to the Lenders or any other obligation of
Borrowers, or any actions now or hereafter taken by the Lenders with respect to any obligation of Borrowers, the Guaranty and Security Agreement (i) is and shall continue to be a primary obligation of such Credit Party, (ii) is and shall
continue to be an absolute, unconditional, continuing and irrevocable guaranty of payment, and (iii) is and shall continue to be in full force and effect in accordance with its terms. Nothing contained herein to the contrary shall release,
discharge, modify, change or affect the original liability of any Credit Party under the Guaranty and Security Agreement. 

3. Acknowledgment of Perfection of Security Interest. Each Credit Party hereby acknowledges that, as of the date
hereof, the security interests and liens granted to Agent, the L/C Issuer and the Lenders under the Credit Agreement and the other Loan Documents are in full force and effect, are properly perfected and are enforceable in accordance with the terms
of the Credit Agreement and the other Loan Documents. 
 4. Effect of Agreement. Except as set forth expressly
herein, all terms of the Credit Agreement, as amended hereby, and the other Loan Documents shall be and remain in full force and effect and shall constitute the legal, valid, binding and enforceable obligations of the Borrowers to the Lenders, the
L/C Issuer and Agent. The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the Lenders under the Credit Agreement, nor constitute a waiver of
any provision of the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement. 

5. Governing Law. This Amendment shall be governed by, and construed in accordance with, the internal laws of
the State of New York and all applicable federal laws of the United States of America. 
 6. No Novation. This
Amendment is not intended by the parties to be, and shall not be construed to be, a novation of the Credit Agreement and the other Loan Documents or an accord and satisfaction in regard thereto. 

  
 3 

 7. Costs and Expenses. The Borrowers agree to pay on demand all costs and
expenses of Agent in connection with the preparation, execution and delivery of this Amendment, including, without limitation, the reasonable fees and out-of-pocket expenses of outside counsel for Agent with respect thereto. 

8. Counterparts. This Amendment may be executed by one or more of the parties hereto in any number of separate
counterparts, each of which shall be deemed an original and all of which, taken together, shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of this Amendment by facsimile transmission, Electronic
Transmission or containing an E-Signature shall be as effective as delivery of a manually executed counterpart hereof. 
 9.
Binding Nature. This Amendment shall be binding upon and inure to the benefit of the parties hereto, their respective successors, successors-in-titles, and assigns. 

10. Entire Understanding. This Amendment sets forth the entire understanding of the parties with respect to the matters
set forth herein, and shall supersede any prior negotiations or agreements, whether written or oral, with respect thereto. 
 [signature
pages to follow] 

  
 4 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above.

  

			
	BORROWERS AND BORROWER REPRESENTATIVE:
	
	 CRYOLIFE, INC.

		
	 By:
	 	 /s/ D. A. Lee

	 Name:
	 	 David Ashley Lee

	 Title:
	 	 EVP, COO & CFO

 [Signature Page to First Amendment to Second Amended and Restated Credit Agreement] 

  

 
			
	BORROWERS:
	
	AURAZYME PHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ D. A. Lee

	 Name:
	 	 D. Ashley Lee

	 Title:
	 	 Executive Vice President, Chief Operating

		 	 Officer and Chief Financial Officer

	
	CRYOLIFE INTERNATIONAL, INC.
		
	 By:
	 	 /s/ D. A. Lee

	 Name:
	 	 D. Ashley Lee

	 Title:
	 	 Executive Vice President, Chief Operating

		 	 Officer and Chief Financial Officer

 [Signature Page to First Amendment to Second Amended and Restated Credit Agreement] 

  

 
			
		 	AGENT, L/C ISSUER AND LENDERS:
		
		 	 GENERAL ELECTRIC CAPITAL

		 	 CORPORATION, as Agent, L/C Issuer and sole Lender

		
	 By:
	 	 /s/ Daniel L. Evans

		 	 Its Duly Authorized Signatory

		 	 Daniel L. Evans

 [Signature Page to First Amendment to Second Amended and Restated Credit Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]